View RSS Feed

Recent Blogs Posts

  1. Staphylococcus aureus Sharing Nutrients to Increase Virulence during Infection

    by , Yesterday at 08:53 AM (Chris Baldwin's Cystic Fibrosis Blog)
    An interesting study performed at the Vanderbilt University demonstrated the ability of bacteria, in this case Staphylococcus aureus, to work together in a mixed population, collectively sharing nutrients to resist drugs like antibiotics.

    There are many ways bacteria can develop resistance to antibiotics, and one way is by changing the way they generate energy and becoming “small colony variants”, which are small and weak. The question has always been - how do bacteria that are less ...
  2. Join Now!!!
  3. New insights into bacterial growth in CF lung infection

    by , Yesterday at 01:13 AM (Chris Baldwin's Cystic Fibrosis Blog)
    Researchers from the University of Copenhagen have shown for the first time how bacteria can grow directly in the lungs of Cystic fibrosis patients, giving them the opportunity to get tremendous insights into bacteria behavior and growth in chronic infections.

    The study also discovered the bacterial growth in chronic lung infections among cystic fibrosis (CF) patients was halted or slowed down by the immune cells. The researchers discovered the immune cells consumed all the oxygen and ...
  4. Median age of survival for CFers surpasses 50 years of age!

    by , Yesterday at 12:40 AM (Chris Baldwin's Cystic Fibrosis Blog)
    In a press release from the Canadian Cystic Fibrosis Foundation on Oct. 15, 2014:

    The median age of survival for Canadian cystic fibrosis (CF) patients continues to increase in an upward trend – currently estimated to be 50.9 years of age, it is among the highest in the world. This milestone was recently announced at the North American Cystic Fibrosis Conference in Atlanta, Georgia.

    Based on the most recent Canadian Cystic Fibrosis Registry data, revealing clinical trends
  5. Some doubts for Kalydeco in R117H patients

    by , 10-18-2014 at 05:16 PM (Chris Baldwin's Cystic Fibrosis Blog)
    Vertex would like to add patients with R117H mutations into the Kalydeco patient pool. But they are facing some resistance from the FDA. R117H mutation "results in a functionally different chloride channel than with the G551D mutation", Kalydeco's original indication. In a trial to examine R117H, requested by the FDA, Kalydeco missed its primary endpoint. But Vertex has said it believes there's hope for the drug in that population, potentially in a subpopulation of patients, like those ...
    Tags: kalydeco, r117h
    CF Treatment
  6. Parion Sciences Announces $15.6 Million in Grant Support for Pulmonary Research

    by , 10-18-2014 at 04:00 PM (Chris Baldwin's Cystic Fibrosis Blog)
    Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that the National Institutes of Health (NIH) has awarded up to $15.6 million over 5 years in grants to The University of North Carolina, Chapel Hill (UNC-CH) and The University of Colorado, Denver (UCD) to conduct research with mucolytic agents discovered by Parion Sciences and to enable Investigational New Drug (IND) applications for Parion’s molecules.

    The ...

    Updated Yesterday at 12:48 AM by ChrisBaldwin

    Tags: asl
    CF Treatment
Page 1 of 62 1231151 ... LastLast